Aurora Cannabis Reports Q2 Revenue Growth

LOS ANGELES- Aurora Cannabis Inc. announced a 29% increase in revenue for the second quarter of fiscal 2025, reaching $81.1 million. This growth is attributed primarily to the rising demand for its medical cannabis products in international markets, with the company forecasting continued strength in this segment as it moves into the third quarter.

Medical cannabis sales accounted for $61.3 million, or 76% of the quarterly revenue, marking a 41% year-over-year increase. Growth in markets such as Australia, Germany, Poland, and the United Kingdom played a significant role, with international medical cannabis sales surpassing Canadian sales for the first time. This shift aligns with Aurora’s strategic focus on high-margin medical cannabis over consumer cannabis, which saw a 13% revenue decline to $10.4 million. According to CEO Miguel Martin, this focus on global medical markets is central to Aurora’s growth strategy.

Aurora’s plant propagation division, Bevo, reported $8.6 million in revenue, a 21% increase from the same period last year, despite seasonal variability. While gross margins in this segment slightly declined due to increased logistics costs, Bevo’s performance underscores its role in supporting Aurora’s broader revenue diversification efforts.

Aurora reported a net income of $1.7 million, a substantial increase from $0.4 million in Q2 2024, driven by higher gross profit despite a decline in other income. The company’s operating expenses decreased slightly as a result of cost-control measures. Aurora achieved a record adjusted EBITDA of $10.1 million, up from $3.3 million in the prior year, illustrating the impact of its efficiency initiatives. Although free cash flow was negative at $26.4 million, this marks an improvement from the previous year’s negative $29.5 million.